

VERSION DATE: 06/12/2026

## **SPIROMICS and SOURCE Abstract Funding Statement**

All SPIROMICS and SOURCE abstracts are required to use the following statement:

SPIROMICS and SOURCE were supported by contracts from the NIH/NHLBI (HHSN2682009000, 75N92024D00012 and 75N92025D00023), grants from the NIH/NHLBI (U01HL137880, U24HL141762, R01HL182622, R01HL144718, R01HL093081 R01HL178727, and R01HL144718), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from Amgen; AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; Genentech; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; Johnson & Johnson; MGC Diagnostics; Novartis Pharmaceuticals Corporation; Nycomed GmbH; Polarean; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; Theravance Biopharma; Merck/Verona; and Mylan/Viatris.

The authors thank RESTECH for their contribution and partnership regarding the oscillometers used.